Australian biotech market watch 09/10/09
Friday, 09 October, 2009
The All Ordinaries has shed some of the gains made over the past couple of days to level out around 4,753 as of 1pm this afternoon.
However, the S&P/ASX 200 Health Care index has underperformed the rest of the market, dropping 176 points to 8,428.
A large portion of that drop can be attributed to a 2.5% fall in CSL (ASX:CSL) to $31.89, closely followed by Primary Health Care (ASX:PRY), which also shed 2.5%, down to $6.34, as well as Cochlear (ASX:COH), which lost $1.42, or 2.1%, to $64.84.
Ansell (ASX:ANN), which has had a good run this week, plateaued around $10.59, down 15c from yesterday's close.
Ramsay Health Care (ASX:RHC) saw an early rally, but has since dropped back 8c below yesterday's close to sit at $10.64.
On the up side, ResMed (ASX:RMD) experienced a 1.8% lift to $5.06, and Blackmores (ASX:BKL) hit a 12 month high of $21.27.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
